H.C. Wainwright downgraded Checkpoint Therapeutics (CKPT) to Neutral from Buy with a price target of $4.10, down from $20, following the acquisition by Sun Pharmaceuticals. The is “please with the outcome,” noting Checkpoint is being acquired at $4.10 per share and a 70c contingent value right.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CKPT: